Cosentyx of Novartis Gets US FDA approval in Pediatric Plaque Psoriasis
Posted on04 Jun 2021
Tagscornerstone cytokine, cosentyx, Cosentyx for plaque psoriasis, novartis, Novartis got approval for Cosentyx, Plaque psoriasis, psoriasis
Comments0
The U.S. Food and Drug Administration (FDA) has approved Novartis’ blockbuster drug Cosentyx® (secukinumab) for pediatric patients aged six years and older with moderate-to-severe plaque psoriasis.... Read More
Insight on Novartis’s first-of-its-kind not-for-profit medicine portfolio for symptomatic treatment of COVID-19
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major... Read More
Case study: Novartis to acquire The Medicines Company for $9.7 billion, get hold of inclisiran, a cholesterol drug
Novartis, a one of the leading global pharmaceutical company, to acquire The Medicines Company for $9.7 billion. Strategic reasoning of the deal:... Read More
Top 10 Global Pharmaceutical Company in 2018
Posted on26 May 2019
Comments0
Novartis’ Cosentyx received CFDA (Chainese) approval to treat adults with plaque psoriasis
Posted on03 Apr 2019
Comments0
Novartis, a global leader in immuno-dermatology and rheumatology, announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A)... Read More
Novartis’s Multiple Sclerosis Drug Mayzent received USFDA approval
Swiss pharma giant Novartis snagged regulatory approval in the United States for its new multiple sclerosis treatment Mayzent (siponimod) and plans to... Read More
Novartis licenses lipoprotein-lowering CVD drug AKCEA-APO(a)-LRx
Posted on26 Feb 2019
Comments0
Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ AKCEA-APO(a)-LRx, a treatment to reduce the risk... Read More
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
Posted on18 Dec 2018
TagsAveXis, global pharma deals, global pharma licensing deal, novartis, pharma acquisition, pharma deal
Comments0
Novartis has agreed to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Novartis app for opium addicts gets US approval
Sandoz Inc., a division of Swiss pharmaceutical giant Novartis, and US company Pear Therapeutics announced this week that the the U.S. Food... Read More